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The generation of the human iPSC line, GFM1SV.25, was carried out
using non-integrative Sendai viruses containing the reprogramming
factors, OCT3/4, SOX2, CMYC, KLF4 (Takahashi et al., 2007). For this pur-
pose, ﬁbroblasts from a described patient with a severe mitochondrial
encephalopathy were obtained (Brito et al., 2015). The patient's ﬁbro-
blasts carried two inherited heterozygous mutations in the GFM1 gene
(c.1404delA; p.Gly469Valfs*84 and c.2011CNT; p.Arg671Cys). The pres-
ence of thesemutations in the iPSC linewas evaluated and conﬁrmed by
Sanger sequencing (Fig. 1A). GFM1SV.25 iPSC colonies displayed a typ-
ical ES-like colony morphology and growth behavior (Fig. 1B) and they
stained positive for alkaline phosphatase activity (Fig. 1C). We con-
ﬁrmed the clearance of the vectors and the exogenous reprogramming
factor genes by RT-PCR after eight culture passages (Fig 1D). The en-
dogenous expression of the pluripotency associated transcription
factors OCT4, SOX2, KLF4,NANOG, CRIPTO and REX1was also evaluated
by RT-PCR (Fig. 1E). Immunoﬂuorescence analysis revealed expression
of transcription factors OCT4, NANOG, SOX2 and surface markers
SSEA3, SSEA4, TRA1-60 and TRA1-81 characteristics of pluripotent ES
cells (Fig. 1F). Promoters of the pluripotency associated genes, OCT4
and NANOG, heavily methylated in the original ﬁbroblasts were
almost demethylated in the GFM1SV.25 line suggesting an epigenetic
reprogramming to pluripotency (Fig. 1G). The iPSC line has been
adapted to feeder-free culture conditions and displays a normal
karyotype (46, XX) after more than twenty culture passages (Fig. 1H).
We also conﬁrmed by DNA ﬁngerprinting analysis that the linethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Molecular and functional characterization of the GFM1SV.25 iPSC line. A. Electropherograms showing themutations in the patient's ﬁbroblasts and in the GFM1SV.25 line. B. Typical
ES-like colony morphology of the GFM1SV.25 iPSC line. C. Positive phosphatase alkaline staining. D. RT-PCR for detecting the clearance of the vectors and the exogenous reprogramming
factor genes. E. QPCR showing the expression of the pluripotency associated markers NANOG, OCT4, SOX2, KLF4, CRIPTO and REX1. F. Immunoﬂuorescence analysis showing expression of
typical pluripotent ES cell markers such as the transcription factors OCT4, NANOG, SOX2 and the surface markers SSEA3, SSEA4, TRA1-60 and TRA1-81; scale bars: 300 μm. G. Bisulﬁte
pyrosequencing of the OCT4 andNANOG promoters. The promoters of the transcription factors, OCT4 andNANOGwere almost demethylated in the generated iPSC line. H. Karyotype anal-
ysis. GFM1SV.25 has a normal karyotype (46, XX). I. DNA ﬁngerprinting analysis showing that GFM1SV.25 comes from the patient's ﬁbroblasts. 1 J. Embryoid body based in vitro differ-
entiation assays. GFM1SV.25 differentiates into all three germ layers, demonstrated by positive AFP endoderm staining (l), positive Tuj1 ectoderm staining and positive SMAmesoderm
staining.
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the capacity of the generated iPSC line to differentiate into the three
germ layers (endoderm, mesoderm and ectoderm) was tested in vitro
using an embryoid body based assay (Fig. 1J).
3. Materials and methods
3.1. Non- integrative reprogramming of mutant GFM1 ﬁbroblasts into iPSC
All the experimental protocols included in the present study were
approved by the Institutional Ethical Committee of the Autonoma Uni-
versity of Madrid according to Spanish and European Union legislation.
Human ﬁbroblasts from a described patient presenting with a severe
mitochondrial encephalopathy associated with mutations in the GFM1
gene were used (Brito et al., 2015). For this purpose tissue fragments
were obtained from a skin biopsy of this patient after informed consent.
These fragmentswere directly plated in a dishwith DMEMhigh glucose
with 10% deﬁned fetal bovine serum (Hyclone), 2 mM GlutaMAX and
1× Penicillin- Streptomycin (Life Technologies). After 3–4 weeks, ﬁbro-
blasts outgrowing from the biopsy pieceswill covermost of the dish and
were expanded at 37 °C in 5% CO2 until the second passage. Subse-
quently, these ﬁbroblasts were reprogrammed using the CytoTune-iPS
2.0 Sendai reprogramming kit following the instructions of the manu-
facturer. After eight passages of the iPSC line, silencing of the exogenous
reprogramming factors genes and Sendai virus genome was conﬁrmed
by RT-PCR following the manufacturer's instructions. GFM1SV.25 was
maintained and expanded both on feeder layers and on feeder-free
layers. In the ﬁrst case, irradiated human ﬁbroblasts feeders with ES
medium containing: Knockout DMEM (Life technologies), Knockout
serum replacement 20%, (Life technologies), MEM non-essential
amino acids solution 1× (Life technologies), GlutaMAX 1× (Life
technologies), β-mercaptoethanol (100 μM), penicillin/streptomy-
cin 1× (Life technologies) and bFGF (4 ng/ml) (Miltenyi Biotec)
were used. Subsequently, GFM1SV.25 was adapted and cultured in
feeder-free conditions onmatrigel (354277, Corning)withmTeSR1me-
dium (StemCell) following the recommendations of the manufacturer.
For the propagation of the line, both enzymatic (dispase, collagenase
IV and accumax) and mechanical procedures have been used.
3.2. Phosphatase alkaline analysis
The iPSC line GFM1SV.25 was seeded on a feeder layer plate. After
seven days direct phosphatase alkaline activity was determined using
the phosphatase alkaline blue membrane substrate solution kit
(Sigma, AB0300) following the instructions of the manufacturer.
3.3. Mutation analysis
Total DNA from the patient's ﬁbroblasts and iPSCs was extracted
using a standard phenol-chloroform protocol. Subsequently, ampliﬁca-
tion by PCR of the GFM1 gene region containing the c.1404delA
mutation (exon 12) and the c.2011C N Tmutation (exon 16)was carried
out using the following primers: For detection of the c.1404delA muta-
tion (GFM1-12F: 5′-GAGTTAAGTCTTGGACTCTTG-3′ and GFM1-12R: 5′-
GAAGCAGTAGACCACATCTG-3′). For detection of the c.2011CNT muta-
tion (GFM1-16F: 5′-CAGGAAAAATGAGTCTAGGTC-3′ and GFM1-16R:
5′-CTTTTTAATTTGTCCATCTGTGC-3′) Following PCR ampliﬁcation,
direct sequencing of amplicons was performed on both strands in an
ABI 3730 sequencer (Applied Biosystems; Foster City, CA) using a dye
terminator cycle sequencing kit (Applera, Rockville, MD).
3.4. qPCR analyses
Total mRNAwas isolated using TRIZOL and 1 μg was used to synthe-
size cDNA using theQuantitect reverse transcription cDNA synthesis kit.
One μl of the reaction was used to quantify by qPCR the expression ofthe endogenous pluripotency associated genes (OCT4, SOX2, KLF4,
NANOG, CRIPTO and REX1). Primers sequences were described by
Aasen et al., 2008. All the expression values were normalized to the
GAPDH housekeeping gene. Plots are representative of at least three in-
dependent experiments.
3.5. Bisulﬁte pyrosequencing
Bisulﬁte modiﬁcation of genomic DNA was performed with the
EZ DNA Methylation-Gold kit (Zymo Research) following the
manufacturer's instructions. The set of primers for PCR ampliﬁcation
and sequencing of NANOG and OCT4 were designed using the software
PyroMark Assay Design (version 2.0.01.15; Qiagen): Forward-NANOG
(5´-TAT TGG GAT TAT AGG GGT GGG TTA-3´), Reverse-NANOG (5´-
[Btn]- CCC AAC AAC AAA TAC TTC TAA ATT CAC-3´), and sequencing
primer S-NANOG (5´-ATA GGG GTG GGT TAT-3´); Forward-OCT4_prox
(5´- GGG GTT AGA GGT TAA GGT TAG TG-3´), Reverse-OCT4_prox (5´-
[Btn]- ACC CCC CTA ACC CAT CAC-3´), and sequencing primer S-
OCT4_prox (5´-GGG GTT GAG TAG TTT-3´); Forward-OCT4_dist (5´- TTT
TTG TGG GGG ATT TGT ATT GA-3´), Reverse-OCT4_dist (5´-[Btn]- AAA
CTA CTC AAC CCC TCT CT-3´), and sequencing primer S-OCT4_dist (5´-
ATT TGT ATT GAG GTT TTG GA-3´). PCR was performed with primers
biotinylated to convert the PCR product to single-stranded DNA
templates, using the Vacuum Prep Tool. After PCR ampliﬁcation, pyrose-
quencing reactions and methylation quantiﬁcation were performed
using PyroMark Q24 reagents, equipment and software (version 2.0.6;
Qiagen), according to the manufacturer's instructions.
3.6. Karyotype analysis
Karyotype analyses of the iPSC line were carried out using cells with
more than twenty culture passages. These cells were processed using
standard cytogenetic techniques. Brieﬂy, cells were treated with
10 μg/mL of Colcemid (Gibco) for 90 min at 37 °C, trypsinized, treated
with 0.075 M hypotonic KCl solution, and ﬁxed with Carnoy's ﬁxative.
Cells were then dropped on a microscope glass slide and dried. Meta-
phase cells were G banded using Wright staining. At least 20 meta-
phases were karyotyped.
3.7. Immunoﬂuorescence analysis
Cells were grown on 0.1% gelatin-coated P35 culture plates (81156,
Ibidi) and ﬁxed with 4% paraformaldehyde. The following antibodies
for the staining were used: TRA-1-60 (Millipore; MAB4360; 1:150);
TRA-1-81 (Millipore; MAB4381; 1:150); SOX2, (Thermo Scientiﬁc;
PA116968; 1:100); NANOG (R&D Systems; AF1997; 1:25); SSEA-4
(Millipore; MAB4304; 1:10); SSEA-3 (Millipore; MAB4303; 1:10);
OCT4 (Santa Cruz Biotechnology; Sc-5279; 1:100); neuron-speciﬁc
class III beta-tubulin (Tuj1) (Sigma, T8660, 1:300), α-fetoprotein
(AFP) (Sigma, WH0000174M1, 1:300), smooth muscle alpha actin
(SMA) (Sigma, A2547, 1:400). Secondary antibodies used were all
from the Alexa Fluor Series from Jackson Immunoresearch (all 1:500).
Images were taken using a Zeiss confocal microscope.
3.8. In vitro differentiation assay
The in vitro pluripotency capacity of the iPSC line was tested by
spontaneous embryoid body differentiation. For this purpose, iPSCs
from a P100 plate with 80% of conﬂuencywere dissociated into a single
cell suspension with accumax (SCR006, Millipore) and resuspended in
12ml ofmTeSR1medium (Stemcell). Embryoid body formationwas in-
duced by seeding 120 μl of the iPSC suspension in each well of 96-well
v-bottom low attachment plates and centrifuging the plates at 800 g
for 10 min to aggregate the cells. After 2–3 days the embryoid bodies
were transferred to an untreated P60 culture plate for 2–4 days. Subse-
quently, the embryoid bodies were transferred to 0.1% gelatin-coated
127F. Zurita-Díaz et al. / Stem Cell Research 16 (2016) 124–127P35 culture plates (81156, Ibidi) and cultured in differentiationmedium
(DMEM F12 supplemented with 20% fetal bovine serum, 2 mM gluta-
mine, 0.1 mM β-mercaptoethanol, 1× non essential amino acids and
1× penicillin–streptomycin, all from Invitrogen) for 2–3 weeks to
allow spontaneous endoderm formation. For mesoderm differentiation,
iPSCs were maintained for 2–3 weeks in differentiation medium
supplemented with 100 μM ascorbic acid (A4403, Sigma-Aldrich).
For ectoderm differentiation, embryoid bodies were transferred to
matrigel coated P35 culture plates and cultured in a special differentia-
tion medium containing (50% DMEM F12, 50% neurobasal medium, 1×
GlutaMAX, 1× penicillin-streptomycin, non essential aminoacids,
0.1 mM 2-mercaptoethanol, 1× N2 supplement and 1× B27 supple-
ment, all from Invitrogen). In all the cases, the medium was changed
every other day.
3.9. DNA ﬁngerprinting analysis
For DNA ﬁngerprinting analysis, highly polymorphic regions con-
taining short tandem repeated sequences of DNA have been evaluated.
For this purpose, the following markers (D13S317, D7S820, VWA,
D8S1179, D21S11, D19S433, D2S1338 and amelogenin for sex determi-
nation) have been ampliﬁed by PCR and analyzed by ABI PRISM 3100
Genetic analyzer and Peak Scanner v3.5 (Applied Biosystems). Primer
sequences and PCR conditions are available upon request.
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